11 September 2020
Sydney's iconic Sun-Herald City2Surf 2020 is on Sunday 18 October 2020, it’s the 50th anniversary and this year the event is virtual, so more people can join in!
Hand sanitiser, social distancing, isolation, working from home…It’s all part of our ’new normal’. For events, the ‘new normal’ means a virtual event. It’s the perfect excuse to get a few mates together, enjoy the day and run, jog or walk 14kms in your neighbourhood to your own beat.
How does the virtual event work?
- Once you've registered you’ll receive an email with a link to download the C2S app
- Anytime between 6am and 6pm* on Sunday 18 October 2020, just open the C2S app and push ‘Start’. You’ll be tracked as if you're doing the actual C2S course - no matter where you are. (*MIA recommend avoiding the middle of the day when the UV rating is higher.)
- When you hit 14kms, the tracking will stop automatically, and your result will be submitted
- Be part of history! All finishers will receive C2S 50 year ‘bling’ (medal) and an exclusive 2020 bandana.
You’re invited to be a Charity Superstar!
Giving back to charity is the beating heart of City2Surf. Melanoma Institute Australia has 20 Charity Superstar places available to our fundraisers. We invite you to become one of 20 MIA Charity Superstars for this year’s City2Surf.
As a Charity Superstar you’ll be part of an exclusive group helping Melanoma Institute Australia achieve our mission of zero deaths from melanoma this decade. You’ll receive the following benefits:
- We’ll cover your C2S entry fee
- You’ll receive a ‘Run over Melanoma’ singlet, MIA hat and SunSense sunscreen
- Be part of the MIA and make a real difference for people impacted by melanoma
- Be rewarded for achieving your fundraising target of $1000 (we’ll support you!)
To apply to become a C2S Charity Superstar please click on the link below:
Together we can run over melanoma!
Visit the City2Surf website for more information about participating in this iconic event.
#City2Surf #LetsRunSydney #RunOverMelanoma.
MIA has launched its first eBook Melanoma Essentials – A Concise Guide, a resource for GPs and other medical, nursing and allied professionals to help them effectively diagnose and manage cases.
Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.
A new melanoma treatment has been listed on the PBS today, giving another option for advanced melanoma patients.
MIA's Pathology Fellow Dr Louise Jackett tells us why she's joined our fellowship program to learn from the best.
MIA doctors and patient have featured in the final episode of ABC’s ground-breaking series Keeping Australia Alive.
Specialist dermatologists at MIA are researching moles during pregnancy and we are looking for study recruits.
New research is re-writing the textbooks on what we know about melanoma by highlighting the effectiveness of radiotherapy as a treatment, reversing a long-held belief that melanoma was resistant to radiotherapy.
However, Australia's burden of melanoma will stay very high over the next 15 years unless we do more. MIA's Professor Graham Mann explains.
Thank you to everyone involved in making Melanoma March 2016 a huge success
Melanoma March 2016 has officially begun with more than 300 people marching in Rockingham and Devonport.
MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.
In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma.
MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.
Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform.
New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
New MIA-led research has been published in the Journal of Clinical Oncology.
Melanoma March was officially launched today with the announcement of the national research project funded by the march.
Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.
Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.
MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen.
Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.